Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $183.00
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price target lifted by Morgan Stanley from $182.00 to $183.00 in a research report released on Friday,Benzinga reports. The firm currently has an equal weight rating on the stock. Several other brokerages have also recently issued reports on NBIX. Stifel Nicolaus raised their target price on Neurocrine […]
14 Sep 05:24 · The Markets Daily